ASH: Celgene's pomalidomide shows durable response in late multiple myeloma
This article was originally published in Scrip
Celgene's pomalidomide appears to produce durable responses in multiple myeloma patients who have failed previous therapies, suggest data from the pivotal Phase III MM-003 presented this week at the American Society of Hematology meeting in Atlanta.
You may also be interested in...
New data from Novo Nordisk supporting its GLP-1 agonist will fortify the firm's new drug applications, strengthen its position in price negotiations and boost its chances of reimbursement.
In an interview at the European Association for the Study of Diabetes meeting, Merck exec Sam Engel explains the rationale behind the clinical trial strategy for the SGLT-2 inhibitor ertugliflozin, as it gears up with partner Pfizer for filings by the end of this year.
Datamonitor Healthcare's Aine Slowey takes an in-depth look at the highlights of this week's annual meeting of the American Society of Hematology (ASH), in New Orleans, Louisiana, focussing on Roche/Biogen Idec's Gazyva, Celgene's Revlimid and Gilead's idelalisib.